173 related articles for article (PubMed ID: 33871762)
1. Are recist criteria adequate in assessing the response to therapy in metastatic NEN?
Vullierme MP; Ruszniewski P; de Mestier L
Rev Endocr Metab Disord; 2021 Sep; 22(3):637-645. PubMed ID: 33871762
[TBL] [Abstract][Full Text] [Related]
2. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
[TBL] [Abstract][Full Text] [Related]
3. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
[TBL] [Abstract][Full Text] [Related]
4. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors.
Ronot M; Dioguardi Burgio M; Gregory J; Hentic O; Vullierme MP; Ruszniewski P; Zappa M; de Mestier L
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101827. PubMed ID: 37858478
[TBL] [Abstract][Full Text] [Related]
5. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
6. Are we reproducible in measurement of NET liver metastasis?
Moalla S; Arfi Rouche J; Foulon S; Caramella C; Ternes N; Planchard D; Goere D; Ducreux M; Scoazec JY; Deschamps F; Dromain C; Baudin E
Dig Liver Dis; 2017 Oct; 49(10):1121-1127. PubMed ID: 28844707
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
8. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
9. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
10. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
12. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
[TBL] [Abstract][Full Text] [Related]
13. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.
Gulpinar B; Peker E; Soydal C; Araz M; Elhan AH
Br J Radiol; 2020 Feb; 93(1106):20190735. PubMed ID: 31922897
[TBL] [Abstract][Full Text] [Related]
14. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?
van Treijen MJC; Schoevers JMH; Heeres BC; van der Zee D; Maas M; Valk GD; Tesselaar MET
Abdom Radiol (NY); 2022 Mar; 47(3):1071-1081. PubMed ID: 34989825
[TBL] [Abstract][Full Text] [Related]
15. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
[TBL] [Abstract][Full Text] [Related]
16. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
18. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
19. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis.
Wang Y; Huang K; Chen J; Luo Y; Zhang Y; Jia Y; Xu L; Chen M; Huang B; Ni D; Li ZP; Feng ST
Contrast Media Mol Imaging; 2018; 2018():6037273. PubMed ID: 30510495
[TBL] [Abstract][Full Text] [Related]
20. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
Løitegård T; Berntzen DT; Thiis-Evensen E
Ann Nucl Med; 2019 Mar; 33(3):147-152. PubMed ID: 30406360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]